Create issue ticket

309 Possible Causes for DOTATOC, 90, Y, Yttrium

Show results in: Română

  • Insulinoma

    Imamura M, Hattori Y, Nishida O, Honda T, Shimada Y, et al.[] Paprottka PM, Hoffmann RT, Haug A, et al, 2012 Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres.[] These three lesions were highly positive on Ga DOTATOC PET/CT, leading to the hypothesis of a malignant insulinoma with neoplastic vein thrombus and ovarian metastasis, which[] An insulinoma is a rare pancreatic endocrine tumor which is typically a hypervascular, solitary small tumour. 90 % of tumors are benign and less than 2 cm in size.[]

  • Glucagonoma

    Material y métodos Se ha realizado una revisión retrospectiva de casos de glucagonoma y seudoglucagonoma entre enero de 1998 y diciembre de 2003 en 3 hospitales.[] NCT01204476 Phase 1 Everolimus;Octreotide Acetate 27 Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer Completed NCT00005842 Phase 1 tipifarnib 28 Yttrium[] Other modes of therapy were as follows: surgery in 3/6 patients, peptide receptor radioligand therapy with (90) Y-DOTATOC (PRRT) in 3/6 patients (two responses) and chemotherapy[] Heart. 2004 Jul;90(7):e44. Author information 1 Department of Medicine, Johns Hopkins Hospital, Baltimore, Maryland 21287, USA.[]

  • Octreotide

    METHODS: Twenty-seven patients with NET were studied by ceCT and standard whole-body PET according to established Ga-DOTATOC protocols.[] Combined long-acting somatostatin analogue (octreotide) and peptide radionuclide receptor ((90)Y-DOTA-TATE) therapy were introduced.[] These were Yttrium-90 and Lutetium-177. Later some doctors tried ... Created on 20 January 2011 16.[] […] packs Max qty units No. of repeats DPMQ Max Safety Net General Patient Charge 6227R MP OCTREOTIDE octreotide 50 microgram/mL injection, 5 x 1 mL ampoules ( PI , CMI ) 18 90[]

  • Carcinoid Neoplasm of the Ovary

    Cuando la crisis no se diagnostica y trata oportunamente, la mortalidad es alta.[] Unresectable tumors can be managed with yttrium-90 labeled octreotide. This targets the tumor and doses it with radioactivity from inside the body.[] The clinical value of [90Y-DOTA]-D-Phe 1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol. 2001;12:941-45.[] In case of metastatic disease, both ovaries are involved and more than 90% of patients have metastases outside the ovary ( Dotto et al., 2008 ).[]

  • Somatostatinoma

    […] leucovorin;oxaliplatin 2 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo 3 Ga-DOTATOC[] The average postoperative 5-year survival rate was 75.2% in 90 patients overall, 59.9% in 44 with metastases and 100.0% in 46 without metastases.[] Arima H 1 , Natsugoe S , Maemura K , Hata Y , Kumanohoso T , Imamura H , Mataki Y , Kurahara H , Shinchi H , Takao S , Aikou T .[] Selective internal radiotherapy (SIRT) This is when microscopic beads that are coated with a radioactive substance called Yttrium-90 are injected into the blood supply to[]

  • Intrahepatic Cholangiocarcinoma

    In particular, radioembolization with Yttrium-90 ( 90 Y)-labeled spheres has been reported to be a promising therapeutic approach for this neoplasia.[] Another clear advantage of Y-90 radioembolization is the excellent tolerance of the therapy and low toxicity.[] Therefore, the use of yttrium-90 microspheres should be considered in the list of available treatment options for ICC.[] Kumamoto T 1 , Tanaka K , Takeda K , Nojiri K , Mori R , Taniguchi K , Matsuyama R , Ueda M , Sugita M , Ichikawa Y , Nagashima Y , Endo I .[]

    Missing: DOTATOC
  • Pancreatic Neoplasm

    […] sobre la patogénesis de enfermedades locales y sistémicas.[] […] addition is the use of peptide receptor radiotherapy (PRRT) using SST as the peptide with a carrier such as 68 Gallium ( 68 Ga) for localization or 177 Lutetium ( 177 Lu) or 99 Yttrium[] Promising data have evolved with regard to peptide receptor-targeted radiotherapy (PRRT) in the treatment of NETs with liver metastases using 90 Yttrium and 177 Lutetium labeled DOTATOC[] We report 3 cases of a previously undescribed variant of solid pseudopapillary tumor of the pancreas composed almost entirely of multivacuolated clear cells ( 90%).[]

  • Iodine-131-Tositumomab

    DOTATOC: A powerful new tool for receptor-mediated radionuclide therapy. Eur. J. Nucl. Med. 1997; 24 :792–795. [ PubMed ] [ Google Scholar ] 54.[] It is the second radioimmunoconjugate to be approved for refractory NHL; yttrium-90 linked to ibritumomab tiuxetan (Zevalin) was approved in 2002.[] Methods: Thirty-eight patients (25 male and 13 female; median age, 64 y) received radioimmuno-therapy for NHL (20 received 90Y-ibritumomab tiuxetan; 18 re-ceived 131I-tositumomab[] 35 30t 4 y2 y 20 234 y21 27the absence of controlled studies.ble 3.[]

  • Carcinoid Tumor

    Endokrynol Pol. 2013;64(6):480-93. doi: Gu Y, Wang N, Xu H. Carcinoid tumor of the appendix: a case report. Oncol Lett. 2015;9(5):2401-3. doi: Rorstad O.[] Unresectable tumors can be managed with yttrium-90 labeled octreotide. This targets the tumor and doses it with radioactivity from inside the body.[] The clinical value of [90Y-DOTA]-D-Phe 1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol. 2001;12:941-45.[] Colonoscopy up to 90 cm showed a stenosing, ulcero-proliferative lesion in the transverse colon. No synchronous lesion was detected.[]

  • Moderately-Differentiated Thymic Neuroendocrine Carcinoma

    Okuma, Y., Hosomi, Y., Watanabe, K., Nakahara, Y., Takagi, Y., Saito, M., & Okamura, T. (2014, May).[] Selective internal radiotherapy with Yttrium-90 microspheres for hepatic metastatic neuroendocrine tumors: a prospective single center study. Digestion 2009;79:137-42.[] About 90% of people with this type live at least 15 years after diagnosis. Type B1 thymoma.[] "Disease control was achieved in over 90% of patients tested," said Giaccone. "This represents a significant advance in the care of these patients.[]